Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Glycine vs Placebo for the Schizophrenia Prodrome

This study has been completed.
Glytech, Inc
National Alliance for Research on Schizophrenia and Depression
Information provided by:
Yale University Identifier:
First received: February 10, 2006
Last updated: January 13, 2010
Last verified: January 2010
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Condition Intervention Phase
Schizophrenia Prodrome
Drug: Glycine
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Glycine vs Placebo for the Schizophrenia Prodrome

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Scale of Prodromal Symptoms total score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: March 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Glycine
Glycine 0.4 g/kg bid
Placebo Comparator: 2
Drug: Placebo


Ages Eligible for Study:   13 Years to 35 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • meet SIPS criteria for schizophrenia prodrome

Exclusion Criteria:

  • history of psychosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00291226

United States, Connecticut
PRIME Clinic
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Glytech, Inc
National Alliance for Research on Schizophrenia and Depression
Principal Investigator: Scott W Woods, MD Yale School of Medicine
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Scott Woods, Yale University School of Medicine Identifier: NCT00291226     History of Changes
Other Study ID Numbers: Glytech  NARSAD Distinguished 2005 
Study First Received: February 10, 2006
Last Updated: January 13, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Yale University:
schizophrenia prodrome

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on December 08, 2016